Applications of oxetanes in drug discovery and medicinal chemistry.

[1]  L. Platanias,et al.  Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer. , 2023, RSC Medicinal Chemistry.

[2]  Jianhua Shen,et al.  Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists. , 2023, Journal of medicinal chemistry.

[3]  Yujia Wen,et al.  Progress in Synthesis and Properties of Oxetane−based Energetic Polymers , 2023, European Polymer Journal.

[4]  Jie Liu,et al.  Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives. , 2023, European journal of medicinal chemistry.

[5]  T. Cierpicki,et al.  2-Aminobenzothiazoles in anticancer drug design and discovery. , 2023, Bioorganic chemistry.

[6]  Donal N. Gorman,et al.  A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus , 2022, Diabetes, obesity & metabolism.

[7]  B. Zetter,et al.  Inhibition of Wnt signaling in colon cancer cells via an oral drug that facilitates TNIK degradation. , 2022, Molecular Cancer Therapeutics.

[8]  Xuejiao Han,et al.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies , 2022, Journal of Hematology & Oncology.

[9]  Qihua Zhu,et al.  Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy , 2022, Molecules.

[10]  Mark S. Sundrud,et al.  Development of a putative Zn2+-chelating but highly selective MMP-13 inhibitor. , 2022, Bioorganic & medicinal chemistry letters.

[11]  A. Tolcher,et al.  488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC) , 2022, Annals of Oncology.

[12]  T. Rana,et al.  Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents , 2022, Journal of medicinal chemistry.

[13]  Dolca Thomas,et al.  Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. , 2022, The New England journal of medicine.

[14]  L. Ouyang,et al.  Targeting EZH2 for cancer therapy: From current progress to novel strategies. , 2022, European journal of medicinal chemistry.

[15]  J. M. Bradshaw,et al.  Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). , 2022, Journal of medicinal chemistry.

[16]  Theodore A. Martinot,et al.  Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. , 2022, Journal of medicinal chemistry.

[17]  R. Su,et al.  FTO in cancer: functions, molecular mechanisms, and therapeutic implications. , 2022, Trends in cancer.

[18]  A. Tiwari,et al.  m6A modification: recent advances, anticancer targeted drug discovery and beyond , 2022, Molecular cancer.

[19]  Changhai Ding,et al.  Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases , 2022, Expert opinion on investigational drugs.

[20]  Fansheng Ran,et al.  Recent development of BTK-based dual inhibitors in the treatment of cancers. , 2022, European journal of medicinal chemistry.

[21]  P. Haycock,et al.  Amino-oxetanes as amide isosteres by an alternative defluorosulfonylative coupling of sulfonyl fluorides , 2022, Nature Chemistry.

[22]  M. Mingueneau,et al.  Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. , 2021, Journal of medicinal chemistry.

[23]  William H. Yang,et al.  Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial , 2021, Nature Medicine.

[24]  Maryne A. J. Dubois,et al.  Investigating 3,3-diaryloxetanes as potential bioisosteres through matched molecular pair analysis , 2021, RSC Medicinal Chemistry.

[25]  A. Howell,et al.  Unusual Transformations of Strain-Heightened Oxetanes. , 2021, Accounts of chemical research.

[26]  A. Poulsen,et al.  Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors. , 2021, Bioorganic & medicinal chemistry.

[27]  P. Tariot,et al.  The case for low-level BACE1 inhibition for the prevention of Alzheimer disease , 2021, Nature Reviews Neurology.

[28]  Hajeung Park,et al.  N-Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors. , 2021, ACS medicinal chemistry letters.

[29]  M. Sawa,et al.  Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase. , 2021, Journal of medicinal chemistry.

[30]  Datong Zhang,et al.  Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases , 2021, Molecules.

[31]  Donal N. Gorman,et al.  Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial , 2021, Nature Medicine.

[32]  D. Berwick,et al.  The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play , 2021, British journal of pharmacology.

[33]  Xiangxuan Zhao,et al.  Targeting Bcl-2 for cancer therapy. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[34]  D. Murrell,et al.  Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study , 2021, The British journal of dermatology.

[35]  B. Jones.  The therapeutic potential of GLP‐1 receptor biased agonism , 2021, British journal of pharmacology.

[36]  Stephen M. Canham,et al.  Phenotypic screen identifies calcineurin-sparing FK506 analogs as BMP potentiators for treatment of acute kidney injury. , 2021, Cell chemical biology.

[37]  Zhijun Li,et al.  Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes , 2021, British journal of pharmacology.

[38]  M. Ecker,et al.  Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis , 2021, International journal of molecular sciences.

[39]  G. Fields,et al.  Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability , 2020, ChemMedChem.

[40]  Hajeung Park,et al.  Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors , 2020, ACS medicinal chemistry letters.

[41]  N. Neamati,et al.  Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. , 2020, European journal of medicinal chemistry.

[42]  Rahul Singh,et al.  Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors. , 2020, European journal of medicinal chemistry.

[43]  Mengjing Zhao,et al.  GDC-0349 inhibits non-small cell lung cancer cell growth , 2020, Cell Death & Disease.

[44]  R. Couñago,et al.  Chemical Space Exploration of Oxetanes , 2020, International journal of molecular sciences.

[45]  Margaret S. Landis,et al.  A small-molecule oral agonist of the human glucagon-like peptide-1 receptor , 2020, bioRxiv.

[46]  T. Borsello,et al.  JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases , 2020, Cells.

[47]  Weijian Guo,et al.  EZH2: a novel target for cancer treatment , 2020, Journal of Hematology & Oncology.

[48]  H. Xu,et al.  Structural insights into the activation of GLP-1R by a small molecule agonist , 2020, Cell Research.

[49]  Z. Ronai,et al.  PRMT5 function and targeting in cancer , 2020, Cell stress.

[50]  P. Geraghty,et al.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics , 2020, Respiratory Research.

[51]  Tao Tao,et al.  mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges , 2020, Cell & Bioscience.

[52]  Patrick J. Curran,et al.  Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). , 2020, ACS medicinal chemistry letters.

[53]  J. Chandrasekhar,et al.  Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. , 2020, ACS medicinal chemistry letters.

[54]  Hua-Lin Wu,et al.  Pharmacological Inhibition of Cathepsin S Suppresses Abdominal Aortic Aneurysm in Mice. , 2020, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[55]  J. Kwiatkowski,et al.  Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2. , 2020, Journal of medicinal chemistry.

[56]  T. Al‐Tel,et al.  BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease , 2020, Medicinal research reviews.

[57]  P. Grandi,et al.  Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a key off-target activity. , 2019, Journal of medicinal chemistry.

[58]  N. Castagnoli,et al.  Metabolism of Strained Rings: Glutathione S-transferase–Catalyzed Formation of a Glutathione-Conjugated Spiro-azetidine without Prior Bioactivation , 2019, Drug Metabolism and Disposition.

[59]  J. McLellan,et al.  Structure of the Respiratory Syncytial Virus Polymerase Complex , 2019, Cell.

[60]  L. Cantley,et al.  Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. , 2019, Bioorganic & medicinal chemistry letters.

[61]  M. A. Hayes,et al.  Hip to be square: oxetanes as design elements to alter metabolic pathways. , 2019, Journal of medicinal chemistry.

[62]  H. Hua,et al.  Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.

[63]  L. Settimo,et al.  Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. , 2019, ACS medicinal chemistry letters.

[64]  J. Wu,et al.  Discovery of Ziresovir as a Potent, Selective and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. , 2019, Journal of medicinal chemistry.

[65]  N. Dzamko,et al.  Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease , 2019, Drugs.

[66]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[67]  R. Yan,et al.  A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment , 2019, CNS Drugs.

[68]  V. Dembitsky,et al.  Oxetane-containing metabolites: origin, structures, and biological activities , 2019, Applied Microbiology and Biotechnology.

[69]  Catherine A. Collins,et al.  An axonal stress response pathway: degenerative and regenerative signaling by DLK , 2018, Current Opinion in Neurobiology.

[70]  J. Wu,et al.  Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. , 2018, Journal of medicinal chemistry.

[71]  Orlistat , 2018, Reactions Weekly.

[72]  Geeta Mehta,et al.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy. , 2018, Journal of medicinal chemistry.

[73]  Xu Wang,et al.  Targeting the IDO1 pathway in cancer: from bench to bedside , 2018, Journal of Hematology & Oncology.

[74]  Joseph W. Lewcock,et al.  Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration. , 2018, Journal of medicinal chemistry.

[75]  A. Dueñas-González,et al.  Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy , 2018, Expert opinion on investigational drugs.

[76]  D. Alessi,et al.  LRRK2 kinase in Parkinson's disease , 2018, Science.

[77]  V. Rosen,et al.  Bone Morphogenetic Protein-Based Therapeutic Approaches. , 2018, Cold Spring Harbor perspectives in biology.

[78]  Adam R. Johnson,et al.  Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. , 2018, Journal of medicinal chemistry.

[79]  B. Zetter,et al.  Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. , 2018, European journal of medicinal chemistry.

[80]  Xiaohua Liu,et al.  Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors. , 2018, Bioorganic & medicinal chemistry.

[81]  Hong C Shen,et al.  Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. , 2017, European journal of medicinal chemistry.

[82]  Jianping Yin,et al.  Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. , 2017, Journal of medicinal chemistry.

[83]  E. Huang,et al.  Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease , 2017, Science Translational Medicine.

[84]  P Gennemark,et al.  Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin‐concentrating Hormone Receptor 1 Antagonist , 2017, CPT: pharmacometrics & systems pharmacology.

[85]  Adam R. Johnson,et al.  Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties , 2017, ACS medicinal chemistry letters.

[86]  M. Masuda,et al.  Emergence of TNIK inhibitors in cancer therapeutics , 2017, Cancer science.

[87]  Jian Jin,et al.  Inhibitors of Protein Methyltransferases and Demethylases , 2017, Chemical reviews.

[88]  L. Lai,et al.  Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity. , 2017, Cell chemical biology.

[89]  L. Byers,et al.  Giving AXL the axe: targeting AXL in human malignancy , 2017, British Journal of Cancer.

[90]  C. Bramham,et al.  Tuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK-eIF4E Axis. , 2016, Trends in biochemical sciences.

[91]  K. F. Morgan,et al.  Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. , 2016, Chemical reviews.

[92]  N. Castagnoli,et al.  Discovery of a Novel Microsomal Epoxide Hydrolase–Catalyzed Hydration of a Spiro Oxetane , 2016, Drug Metabolism and Disposition.

[93]  L. Leclercq,et al.  Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition. , 2016, Journal of medicinal chemistry.

[94]  R. Copeland,et al.  Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[95]  Robert A Copeland,et al.  Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. , 2016, ACS medicinal chemistry letters.

[96]  P. Gennemark,et al.  Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. , 2016, Journal of medicinal chemistry.

[97]  L. Kwanten,et al.  Molecular mechanism of respiratory syncytial virus fusion inhibitors. , 2016, Nature chemical biology.

[98]  Changwei Wang,et al.  Taxane anticancer agents: a patent perspective , 2016, Expert opinion on therapeutic patents.

[99]  Mari Masuda,et al.  Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. , 2015, Pharmacology & therapeutics.

[100]  Asier Unciti-Broceta,et al.  AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. , 2015, Journal of medicinal chemistry.

[101]  K. Scearce-Levie,et al.  Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). , 2015, Journal of medicinal chemistry.

[102]  A. Mahal.  Oxetanes as versatile building blocks in the total synthesis of natural products: An overview , 2015 .

[103]  A. Howell,et al.  Recent Applications of Oxetanes in the Synthesis of Heterocyclic Compounds. , 2015, The Journal of organic chemistry.

[104]  C. Scott,et al.  Cathepsin S: therapeutic, diagnostic, and prognostic potential , 2015, Biological chemistry.

[105]  M. Gill,et al.  Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. , 2015, Journal of medicinal chemistry.

[106]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[107]  E. Dunn,et al.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter , 2015, Journal of Virology.

[108]  J. M. Bradshaw,et al.  Prolonged and tunable residence time using reversible covalent kinase inhibitors , 2015, Nature chemical biology.

[109]  K. Kolibaba,et al.  An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. , 2015, Blood.

[110]  D. Shechter,et al.  The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond , 2015, Cellular and Molecular Life Sciences.

[111]  Yanliang Ren,et al.  Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[112]  K. Scearce-Levie,et al.  Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. , 2015, Journal of medicinal chemistry.

[113]  J. Moreb,et al.  Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? , 2014, Drug discovery today.

[114]  R. Wahl,et al.  Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). , 2014, Journal of medicinal chemistry.

[115]  A. Weymouth-Wilson,et al.  Synthesis and anti-HCV activity of 1-(1′,3′-O-anhydro-3′-C-methyl-β-d-psicofuranosyl)uracil , 2014 .

[116]  Bruce W. Shaw,et al.  Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm. , 2014, ACS medicinal chemistry letters.

[117]  R. Haydon,et al.  Bone Morphogenetic Protein (BMP) signaling in development and human diseases , 2014, Genes & diseases.

[118]  Kenneth D. Johnson,et al.  Characterization of a Respiratory Syncytial Virus L Protein Inhibitor , 2014, Antimicrobial Agents and Chemotherapy.

[119]  R. Beckmann,et al.  CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. , 2014, Pharmacology & therapeutics.

[120]  C. Espiritu,et al.  Use of 2'-spirocyclic ethers in HCV nucleoside design. , 2014, Journal of medicinal chemistry.

[121]  J. Kuriyan,et al.  Crenolanib is a selective type I pan-FLT3 inhibitor , 2014, Proceedings of the National Academy of Sciences.

[122]  K. Scearce-Levie,et al.  Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. , 2014, Journal of medicinal chemistry.

[123]  B. Samuelsson,et al.  Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase. , 2014, Journal of medicinal chemistry.

[124]  M. Levis,et al.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. , 2014, Blood.

[125]  M. Zabel,et al.  The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[126]  A. Tedeschi,et al.  The DLK signalling pathway—a double‐edged sword in neural development and regeneration , 2013, EMBO reports.

[127]  D. Fruman,et al.  Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function , 2013, Proceedings of the National Academy of Sciences.

[128]  S. Sideris,et al.  Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR). , 2013, Journal of medicinal chemistry.

[129]  M. Belvin,et al.  Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. , 2013, ACS medicinal chemistry letters.

[130]  M. Heinrich,et al.  Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.

[131]  C. Pozniak,et al.  DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity , 2011, The Journal of cell biology.

[132]  Abhishek K. Jha,et al.  Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer , 2011 .

[133]  E. Carreira,et al.  Oxetanes as versatile elements in drug discovery and synthesis. , 2010, Angewandte Chemie.

[134]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[135]  Franz Schuler,et al.  Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.

[136]  Hans Clevers,et al.  The kinase TNIK is an essential activator of Wnt target genes , 2009, The EMBO journal.

[137]  G. Cohen,et al.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy , 2009, Cell Death and Differentiation.

[138]  E. Carreira,et al.  Spirocyclic oxetanes: synthesis and properties. , 2008, Angewandte Chemie.

[139]  A. Altman,et al.  Protein kinase C theta (PKCθ) : A key player in T cell life and death , 2007 .

[140]  E. Carreira,et al.  Oxetanes as promising modules in drug discovery. , 2006, Angewandte Chemie.

[141]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[142]  M. Fennell,et al.  Targeting JNK3 for the treatment of neurodegenerative disorders. , 2004, Drug discovery today.

[143]  D. Payan,et al.  Targeting Syk as a treatment for allergic and autoimmune disorders , 2004, Expert opinion on investigational drugs.

[144]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[145]  S. Snyder,et al.  FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[146]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[147]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[148]  A. Heck,et al.  Orlistat, a New Lipase Inhibitor for the Management of Obesity , 2000, Pharmacotherapy.

[149]  G. Plosker,et al.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. , 2000, Drugs.

[150]  J. Snyder,et al.  The oxetane ring in taxol. , 2000, The Journal of organic chemistry.

[151]  M. Hepperle,et al.  The oxetane conformational lock of paclitaxel: structural analysis of D-secopaclitaxel. , 1999, Bioorganic & medicinal chemistry letters.

[152]  H. K. Sluss,et al.  Selective interaction of JNK protein kinase isoforms with transcription factors. , 1996, The EMBO journal.

[153]  Mehana E El-Sayed,et al.  The role of matrix metalloproteinases in osteoarthritis pathogenesis: An updated review. , 2019, Life sciences.

[154]  E. Carreira,et al.  Adventures in drug-like chemistry space: from oxetanes to spiroazetidines and beyond! , 2014, Chimia.

[155]  W. Oh,et al.  Cabazitaxel , 2010, Nature Reviews Drug Discovery.

[156]  S. Kridel,et al.  Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat , 2007, Nature Structural &Molecular Biology.

[157]  A. Altman,et al.  PROTEIN KINASE C IN T CELL ACTIVATION , 2002 .

[158]  L. Ehrenberg,et al.  The Enthalpies of Combustion and Formation of Some 3,3-Disubstituted Oxetanes. , 1971 .